Mitochon Pharmaceuticals Embarks on Groundbreaking Clinical Trial Targeting Four Neurodegenerative Diseases
BLUE BELL, PA — Mitochon Pharmaceuticals recenlty secured approval from the European Medicines Agency (EMA) to initiate a pioneering Phase I/IIa biomarker study, marking a significant milestone in the fight …
Mitochon Pharmaceuticals Embarks on Groundbreaking Clinical Trial Targeting Four Neurodegenerative Diseases Read More